Cellular Origins of the Lymphatic Endothelium: Implications for Cancer Lymphangiogenesis
- PMID: 33071831
- PMCID: PMC7541848
- DOI: 10.3389/fphys.2020.577584
Cellular Origins of the Lymphatic Endothelium: Implications for Cancer Lymphangiogenesis
Abstract
The lymphatic system plays important roles in physiological and pathological conditions. During cancer progression in particular, lymphangiogenesis can exert both positive and negative effects. While the formation of tumor associated lymphatic vessels correlates with metastatic dissemination, increased severity and poor patient prognosis, the presence of functional lymphatics is regarded as beneficial for anti-tumor immunity and cancer immunotherapy delivery. Therefore, a profound understanding of the cellular origins of tumor lymphatics and the molecular mechanisms controlling their formation is required in order to improve current strategies to control malignant spread. Data accumulated over the last decades have led to a controversy regarding the cellular sources of tumor-associated lymphatic vessels and the putative contribution of non-endothelial cells to this process. Although it is widely accepted that lymphatic endothelial cells (LECs) arise mainly from pre-existing lymphatic vessels, additional contribution from bone marrow-derived cells, myeloid precursors and terminally differentiated macrophages, has also been claimed. Here, we review recent findings describing new origins of LECs during embryonic development and discuss their relevance to cancer lymphangiogenesis.
Keywords: development; lymphangiogenesis; lymphatic; origin; tumor.
Copyright © 2020 Gutierrez-Miranda and Yaniv.
Figures

Similar articles
-
Lymphatic Endothelial Cell Progenitors in the Tumor Microenvironment.Adv Exp Med Biol. 2020;1234:87-105. doi: 10.1007/978-3-030-37184-5_7. Adv Exp Med Biol. 2020. PMID: 32040857 Free PMC article. Review.
-
Tumor-associated macrophages induce capillary morphogenesis of lymphatic endothelial cells derived from human gastric cancer.Cancer Sci. 2016 Aug;107(8):1101-9. doi: 10.1111/cas.12977. Epub 2016 Jun 22. Cancer Sci. 2016. PMID: 27227358 Free PMC article.
-
Tumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions.Front Immunol. 2019 Apr 9;10:720. doi: 10.3389/fimmu.2019.00720. eCollection 2019. Front Immunol. 2019. PMID: 31024552 Free PMC article. Review.
-
The lymphatic vasculature: An active and dynamic player in cancer progression.Med Res Rev. 2022 Jan;42(1):576-614. doi: 10.1002/med.21855. Epub 2021 Sep 5. Med Res Rev. 2022. PMID: 34486138 Free PMC article. Review.
-
Role of lymphatic vasculature in regional and distant metastases.Microvasc Res. 2014 Sep;95:46-52. doi: 10.1016/j.mvr.2014.07.004. Epub 2014 Jul 12. Microvasc Res. 2014. PMID: 25026412 Free PMC article. Review.
Cited by
-
Transcriptomic and Functional Evidence for Differential Effects of MCF-7 Breast Cancer Cell-Secretome on Vascular and Lymphatic Endothelial Cell Growth.Int J Mol Sci. 2022 Jun 28;23(13):7192. doi: 10.3390/ijms23137192. Int J Mol Sci. 2022. PMID: 35806196 Free PMC article.
-
CNS-Draining Meningeal Lymphatic Vasculature: Roles, Conundrums and Future Challenges.Front Pharmacol. 2021 Apr 28;12:655052. doi: 10.3389/fphar.2021.655052. eCollection 2021. Front Pharmacol. 2021. PMID: 33995074 Free PMC article. Review.
-
Established, New and Emerging Concepts in Brain Vascular Development.Front Physiol. 2021 Feb 12;12:636736. doi: 10.3389/fphys.2021.636736. eCollection 2021. Front Physiol. 2021. PMID: 33643074 Free PMC article. Review.
-
Generation of specialized blood vessels via lymphatic transdifferentiation.Nature. 2022 Jun;606(7914):570-575. doi: 10.1038/s41586-022-04766-2. Epub 2022 May 25. Nature. 2022. PMID: 35614218 Free PMC article.
-
Cdh5-lineage-independent origin of dermal lymphatics shown by temporally restricted lineage tracing.Life Sci Alliance. 2022 Aug 12;5(11):e202201561. doi: 10.26508/lsa.202201561. Print 2022 Nov. Life Sci Alliance. 2022. PMID: 35961777 Free PMC article.
References
-
- Achen M. G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A. F., et al. (1998). Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. U.S.A. 95 548–553. 10.1073/pnas.95.2.548 - DOI - PMC - PubMed
-
- Achen M. G., Roufail S., Domagala T., Catimel B., Nice E. C., Geleick D. M., et al. (2000). Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. Eur. J. Biochem. 267 2505–2515. 10.1046/j.1432-1327.2000.01257.x - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources